A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas

Launched by MAYO CLINIC · Apr 3, 2014

Keywords

ClinConnect Summary

This clinical trial is studying a new method to plan radiation treatment for patients with malignant gliomas, which are aggressive brain tumors. Traditionally, doctors use MRI scans to see where the tumor is located, but this study is exploring how a special type of scan called 18F-DOPA PET/CT can improve the treatment plan. The 18F-DOPA scan may help doctors better identify tumor areas that need radiation by providing clearer images that show the difference between the tumor and healthy brain tissue. The main goal is to see if this new scan is more effective than the MRI in planning radiation therapy.

To participate in this study, patients must be at least 7 years old and have a confirmed diagnosis of a newly diagnosed or recurrent Grade II or Grade III malignant glioma. They will undergo several scans, including a CT simulation and both the 18F-DOPA PET and standard MRI scans, all at the Mayo Clinic in Rochester. It’s important to note that people with Grade IV gliomas, those who have had prior radiation therapy, or certain medical conditions that prevent them from having MRI or PET scans cannot participate. If eligible, participants can expect to receive close monitoring and care throughout the trial, and they will need to provide consent to allow the researchers to access their medical records for follow-up.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥7 years.
• • Biopsy confirmed newly diagnosed or recurrent WHO Grade II or Grade III malignant glioma.
• • CT simulation, 18F-DOPA PET imaging, and standard of care pre-radiotherapy MRI scans to be performed at Mayo Clinic Rochester.
• • Willing to sign release of information for any follow-up records.
• • Provide informed written consent.
• Exclusion Criteria:
• • Patients diagnosed with WHO grade IV malignant glioma.
• • Patients previously treated with radiation therapy.
• • Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure).
• • Unable to undergo an 18F-DOPA PET scan (e.g. Parkinson's Disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists)
• • Pregnant women
• • Nursing women
• • Men or women of childbearing potential who are unwilling to employ adequate contraception